Astrazeneca (AZN) Common Equity (2016 - 2026)

Astrazeneca has reported Common Equity over the past 17 years, most recently at $47.4 billion for Q1 2026.

For Q1 2026, Common Equity rose 15.2% year-over-year to $47.4 billion; the TTM value through Mar 2026 reached $47.4 billion, up 15.2%, while the annual FY2025 figure was $48.7 billion, 19.45% up from the prior year.
Common Equity for Q1 2026 was $47.4 billion at Astrazeneca, down from $48.7 billion in the prior quarter.
Over five years, Common Equity peaked at $48.7 billion in Q4 2025 and troughed at $35.2 billion in Q3 2022.
A 5-year average of $40.0 billion and a median of $39.2 billion in 2023 define the central range for Common Equity.
On a YoY basis, Common Equity climbed as much as 218.55% in 2022 and fell as far as 11.92% in 2022.
Year by year, Common Equity stood at $37.1 billion in 2022, then grew by 5.69% to $39.2 billion in 2023, then grew by 4.14% to $40.8 billion in 2024, then grew by 19.45% to $48.7 billion in 2025, then decreased by 2.74% to $47.4 billion in 2026.
Business Quant data shows Common Equity for AZN at $47.4 billion in Q1 2026, $48.7 billion in Q4 2025, and $46.0 billion in Q3 2025.

Peer Comparison